Calidi Biotherapeutics Inc [CLDI] stock is trading at $0.79, down -7.07%. An important factor to consider is whether the stock is rising or falling in short-term value. The CLDI shares have gain 6.83% over the last week, with a monthly amount drifted -46.59%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Calidi Biotherapeutics Inc [AMEX: CLDI] stock has seen the most recent analyst activity on November 22, 2023, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $11. Previously, Robert W. Baird started tracking the stock with Outperform rating on October 09, 2023, and set its price target to $9.
Calidi Biotherapeutics Inc [CLDI] stock has fluctuated between $0.58 and $8.30 over the past year. Currently, Wall Street analysts expect the stock to reach $5.5 within the next 12 months. Calidi Biotherapeutics Inc [AMEX: CLDI] shares were valued at $0.79 at the most recent close of the market. An investor can expect a potential return of 596.2% based on the average CLDI price forecast.
Analyzing the CLDI fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -3.24, Equity is 1.93 and Total Capital is 5.6. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.88.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7365 points at the first support level, and at 0.6826 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8478, and for the 2nd resistance point, it is at 0.9052.
Ratios To Look Out For
For context, Calidi Biotherapeutics Inc’s Current Ratio is 0.19. On the other hand, the Quick Ratio is 0.19, and the Cash Ratio is 0.16.
Transactions by insiders
Recent insider trading involved Camaisa Allan, CEO and Chairman of the Board, that happened on Dec 17 ’24 when 10000.0 shares were sold.
